Supplemental material

Appendix I: Search strategies

MEDLINE (Ovid)

1. exp Electrocardiography, Ambulatory/ or exp Electrocardiography/
2. (12-Lead ECG or 12-Lead EKG or 12-Lead Electrocardiography or ECG or EKG or Electrocardiogram or Electrocardiograph or Ambulatory Electrocardiography or Ambulatory Electrocardiography Monitoring or Dynamic Electrocardiography or Electrocardiography Monitoring, Ambulatory or Electrocardiography, Dynamic or Electrocardiography, Holter or Holter ECG or Holter EKG or Holter Electrocardiography or Holter Monitoring or Monitoring, Ambulatory Electrocardiographic or Monitoring, Holter or Extended ECG monitor* or Extended Holter monitor* or Patch ECG* or Wearable ECG monitor* or Continuous hospital telemetry or mobile cardiac outpatient telemetry or Patient triggered event recorder* or implantable loop recorder* or Implantable cardiac monitor* or ICM*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]
3. 1 or 2
4. exp Ischemic Stroke/ or exp Stroke/
5. exp Ischemic Attack, Transient/
6. (CVA or Cerebral Stroke or Cerebrovascular Accident or Cerebrovascular Accident, Acute or Cerebrovascular Stroke or Stroke, Acute or Vascular Accident, Brain or Acute Ischemic Stroke or Cryptogenic Embolism Stroke or Cryptogenic Ischemic Stroke or Cryptogenic Stroke or Ischaemic Stroke or Wake-up Stroke or TIA or Transient Ischemic Attack).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism

supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

7. 4 or 5 or 6
8. exp Atrial Fibrillation/
9. 3 and 6 and 7
10. limit 9 to english language
11. limit 10 to yr="2011 -Current"

EMBASE (Ovid)

12. exp Electrocardiography, Ambulatory/ or exp Electrocardiography/
13. (12-Lead ECG or 12-Lead EKG or 12-Lead Electrocardiography or ECG or EKG or Electrocardiogram or Electrocardiograph or Ambulatory Electrocardiography or Ambulatory Electrocardiography Monitoring or Dynamic Electrocardiography or Electrocardiography Monitoring, Ambulatory or Electrocardiography, Dynamic or Electrocardiography, Holter or Holter ECG or Holter EKG or Holter Electrocardiography or Holter Monitoring or Monitoring, Ambulatory Electrocardiographic or Monitoring, Holter or Extended ECG monitor* or Extended Holter monitor* or Patch ECG* or Wearable ECG monitor* or Continuous hospital telemetry or mobile cardiac outpatient telemetry or Patient triggered event recorder* or implantable loop recorder* or Implantable cardiac monitor* or ICM*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]
14. 1 or 2
15. exp Ischemic Stroke/ or exp Stroke/
16. exp Ischemic Attack, Transient/

17. (CVA or Cerebral Stroke or Cerebrovascular Accident or Cerebrovascular Accident, Acute or Cerebrovascular Stroke or Stroke, Acute or Vascular Accident, Brain or Acute Ischemic Stroke or Cryptogenic Embolism Stroke or Cryptogenic Ischemic Stroke or Cryptogenic Stroke or Ischaemic Stroke or Wake-up Stroke or TIA or Transient Ischemic Attack).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
18. 4 or 5 or 6
19. exp Atrial Fibrillation/
20. 3 and 6 and 7
21. limit 9 to english language
22. limit 10 to yr="2011 -Current"

Cochrane (CENTRAL)

#1. MeSH descriptor: [Electrocardiography] explode all trees
#2. MeSH descriptor: [Electrocardiography, Ambulatory] explode all trees
#3. (12 Lead ECG or 12 Lead EKG or 12 Lead Electrocardiography or ECG or EKG or Electrocardiogram or Electrocardiograph or Ambulatory Electrocardiography or Ambulatory Electrocardiography Monitoring or Dynamic Electrocardiography or Electrocardiography Monitoring, Ambulatory or Electrocardiography, Dynamic or Electrocardiography, Holter or Holter ECG or Holter EKG or Holter Electrocardiography or Holter Monitoring or Monitoring, Ambulatory Electrocardiographic or Monitoring, Holter or Extended ECG monitor* or Extended Holter monitor* or Patch ECG* or Weable ECG montior* or Continuous hospital telemetry or Mobile cardiac outpatient telemetry or Patient triggered event recorder* or

Prolonged ambulatory ECG or Implantable loop recorder* or Implantable cardiac monitor* or ICM*):ti,ab,kw

#4. #1 or #2 or #3

#5. MeSH descriptor: [Stroke] explode all trees

#6. MeSH descriptor: [Ischemic Stroke] explode all trees

#7. MeSH descriptor: [Ischemic Attack, Transient] explode all trees

#8. (CVA or Cerebral Stroke or Cerebrovascular Accident or Cerebrovascular Accident, Acute or Cerebrovascular Stroke or Stroke, Acute or Vascular Accident, Brain or Acute Ischemic Stroke or Cryptogenic Embolism Stroke or Cryptogenic Ischemic Stroke or Cryptogenic Stroke or Ischaemic Stroke or Wake-up Stroke or Transient Ischemic Attack or TIA or Embolic Stroke of Unknown Source or ESUS):ti,ab,kw

#9. #5 or #6 or #7 or #8

#10. MeSH descriptor: [Atrial Fibrillation] explode all trees

#11. #4 and #9 and #10 with Publication Year from 2011 to 2021

Appendix II: Overview of all studies

Study ID	Design	Country	Condition	Monitoring method	Duration of monitoring	Sample size	No. of AF	Prevalence of AF	Mean/median age
Acampa 2019	Cohort study (Single-center)	Italy	Stroke	Inpatient monitoring	1 week	222	44	19.8%	70.4
Bettin 2019	Cohort study (Single-center)	Germany	Stroke	ILR	24 months	173	33	19.1%	61.4
Brachmann 2016	Randomised Controlled Trial	Europe, Canada, USA	Both	ILR	36 months	221	42	30%	61.6
Christensen 2014	Cohort study (Single-center)	Denmark	Stroke	ILR	18 months	85	14	20.7%	58.0
Cotter 2013	Cohort study (Single-center)	UK	Stroke	ILR	6 months	51	13	25.5%	52.0
Cuadrado-Godia 2020	Cohort study (Single-center)	Spain	Both	ILR	30 months	65	38	58.5%	75.6
DeAngelis 2020	Cohort study (Single-center)	Italy	Stroke	ILR	30 months	58	24	41%	68.1
Flint 2012	Cohort study (Multi-center)	USA	Stroke	MCOT	1 month	239	26	6.7%	64.6

Fonseca 2014	Cohort study (Single-center)	Portugal	Both	Inpatient monitoring	24h	264	17	20.8%	58.6
Gladstone 2014	Randomised Controlled Trial	Canada	Both	MCOT	1 month	286	44	15.5%	72.5
Israel 2017	Cohort study (Single-center)	Germany	Stroke	ILR	12 months	123	29	23.6%	65.0
Jorfida 2016	Cohort study (Single-center)	Italy	Stroke	ILR	36 months	54	25	46%	67.8
Jung 2020	Cohort study (Single-center)	South Korea	Stroke	Inpatient monitoring	24h	125	32	25.6%	65.3
Kitsiou 2021	Cohort study (Single-center)	Germany	Stroke	ILR	36 months	123	51	41.4%	65.0
Koh 2021	Randomised Controlled Trial	Malaysia	Both	MCOT	1 month	105	10	9.5%	65.3
Kulach 2021	Cohort study (Single-center)	Poland	Stroke	MCOT	1 month	72	1	1.4%	59.0
Kulach 2019	Cohort study (Single-center)	Poland	Stroke	MCOT	7 days	78	7	9%	60.0
Lee 2015	Cohort study (Single-center)	Singapore	Both	Inpatient monitoring	3 days	127	12	9.4%	66.0

Liantinioti 2017	Cohort study (Single-center)	Greece	Stroke	Inpatient monitoring	24h	184	13	7%	57.0
Liantinioti 2019	Cohort study (Single-center)	Greece	Stroke	Inpatient monitoring	24h	373	29	8%	60.0
Lips 2020	Cohort study (Single-center)	Germany	Both	ILR	30 months	88	19	21.6%	66.5
Lumikari 2019	Cohort study (Single-center)	Finland	Stroke	MCOT	1 month	57	7	12.3%	64.5
Lumikari 2020	Cohort study (Single-center)	Finland	Stroke	MCOT	2 weeks	15	1	6.7%	59. 5
Lyren 2020	Cohort study (Single-center)	Sweden	Both	MCOT	1 month	100	9	9%	67.6
Makimoto 2017	Cohort study (Single-center)	Germany	Stroke	ILR	12 months	146	30	21%	62.0
Manina 2014	Cohort study (Single-center)	Italy	Both	MCOT	4 days	114	12	24.3%	63.1
Milstein 2020	Cohort study (Single-center)	USA	Stroke	ILR	12 months	343	67	5% (30 days) 21% (1 year)	68
Muller 2017	Cohort study (Single-center)	Germany	Stroke	ILR	12 months	90	16	18%	57.7
Pagola 2018	Cohort study (Single-center)	Spain	Stroke	MCOT	1 month	146	32	21.9%	76.0

Pagola 2021	Cohort study (Multi-center)	Spain	Stroke	MCOT	1 month	253	54	21.3%	74.4
Pedersen 2018	Cohort study (Single-center)	Denmark	TIA	ILR	12 months	105	7	6.7%	65.4
Petrovicova 2021	Cohort study (Single-center)	Slovak Republic	Both	ILR	12 months	100	24	24%	70.1
Poli 2016	Cohort study (Single-center)	Germany	Both	ILR	12 months	75	25	33.3%	66.4
Poulsen 2017	Cohort study (Single-center)	Denmark	Both	MCOT	1 month	95	20	21.1%	78
Rabinstein 2013	Cohort study (Single-center)	USA	Stroke	MCOT	3 weeks	64	3	4.7%	67.9
Reinke 2018	Cohort study (Single-center)	Germany	Stroke	ILR	24 months	105	19	18%	64.4
Riordan 2020	Cohort study (Single-center)	USA	Stroke	ILR	24 months	293	74	25%	67.5
Ritter 2013	Cohort study (Single-center)	Germany	Stroke	ILR, MCOT	12 months (ILR) 7 days (MCOT)	60	10 (ILR) 1 (MCOT)	17%	63.0
RubioCampal 2020	Cohort study (Single-center)	Spain	Both	MCOT	3 weeks	50	11	22%	69.0
Sanak 2015	Cohort study (Single-center)	Czech Republic	Stroke	MCOT	3 weeks	95	9	9.5%	39.1

Seow 2018	Cohort study (Single-center)	Singapore	Both	ILR	12 months	71	11	12.9% (6 months) 15.2% (12 months)	61.9
Toyoda 2021	Cohort study (Multi-center)	Japan	Stroke	MCOT	1 week	206	13	6.3%	71.0
Triantafyllou 2020	Cohort study (Single-center)	Greece	Both	ILR, Inpatient monitoring	18 months (ILR) 24h (Inpatient monitoring)	373 Holter; 123 ILR/ICM	26 (ILR) 28 (Inpatient monitoring)	7.5% (Holter) 21.1% (ICM)	60.0
Tu 2014	Cohort study (Single-center)	Australia	Stroke	MCOT	3 weeks	20	1	5.0% (28 days), 20.0% (2 years)	66.0
Ungar 2021	Cohort study (Multi-center)	Italy	Stroke	ILR	24 months	334	92	27.5%	67.4
Victor 2018	Cohort study (Single-center)	Spain	Stroke	ILR	24 months	65	12	29.2%	65.4
Yayehd 2015	Cohort study (Single-center)	France	Stroke	MCOT	3 weeks	39	1	2.6%	48.0

USA: United States of America; UK: United Kingdom; AF: Atrial fibrillation; ILR: Implantable loop recorder; MCOT: Mobile cardiac outpatient telemetry

Table S1. Overview of study characteristics

Appendix III: Additional forest plots



Figure S1. Overall pooled AF detection rates



Figure S2. Pooled AF detection rates for ILRs and MCOTs at 1 month



Figure S3. Pooled AF detection rates for inpatient monitoring devices



Figure S4. Pooled AF detection rates for ILRs by AF cut-off duration



Figure S5. Pooled AF detection rates for MCOTs by AF cut-off duration



Figure S6. Pooled AF detection rates for ILRs by timing of device implantation



Figure S7. Pooled AF detection rates for MCOTs by timing of device implantation



Figure S8. Pooled AF detection rates for MCOTs by type of device



Figure S9. Pooled AF detection rates by frequency of monitoring at 28 days

Appendix IV: Comparison of study populations

Cohort characteristics	Studies using ILR	Studies using MCOT	Significantly different? (P value)
Total no of studies	23	19	-
No of participants	2870	2094	-
Average age	65.0 +/- 4.0	67.3 +/- 6.4	<0.0001
Average CHA_2DS_2-VASc	3.3 +/- 1.5 (n=21)	2.2 +/- 2.2 (n=12)	<0.0001
Timing of device implantation	38.8 +/- 48.2 (n=17)	20.7 +/- 36.4 (n=13)	<0.0001

Table S1. Comparison of study populations

Study ID	Monitoring method	Duration of monitoring	Sample size	No. of AF	Prevalence of AF	Mean/ median age	CHA_2DS_2-VASc	NIHSS	Rankin	LVEF
Acampa 2019	Inpatient monitoring	1 week	222	44	19.8%	70.4	5 (1.2)	NR	NR	NR
Bettin 2019	ILR	24 months	173	33	19.1%	61.4	4 (1.4)	NR	NR	NR
Brachmann 2016	ILR	36 months	221	42	30%	61.6	2.96	1.6 (2.7)	NR	NR
Christensen 2014	ILR	18 months	85	14	20.7%	58.0	4	0 (range 0-1)	NR	NR
Cotter 2013	ILR	6 months	51	13	25.5%	52.0	3 (IQR 2-4)	NR	NR	NR
Cuadrado-Godia 2020	ILR	30 months	65	38	58.5%	75.6	4.5 (IQR 4-5)	2.2 (range 2-14)	0 (IQR 0-1)	NR
DeAngelis 2020	ILR	30 months	58	24	41%	68.1	4.4 (1.4)	4.4 (2.1)	NR	61.5 (4.0)
Flint 2012	MCOT	1 month	239	26	6.7%	64.6	NR	4.2 (4.5)	1.0 (0.1)	58.1 (6.4)

Fonseca 2014	Inpatient monitoring	24h	264	17	20.8%	58.6	NR	13 (IQR 12)	NR	NR
Gladstone 2014	MCOT	1 month	286	44	15.5%	72.5	3 (range 2-6)	NR	NR	NR
Israel 2017	ILR	12 months	123	29	23.6%	65.0	4.5 (1.3)	3	2 (IQR 2)	59.6 (2.4)
Jorfida 2016	ILR	36 months	54	25	46%	67.8	4.5 (1.2)	NR	NR	60 (6.1)
Jung 2020	Inpatient monitoring	24h	125	32	25.6%	65.3	2.7 (1.5)	NR	NR	NR
Kitsiou 2021	ILR	36 months	123	51	41.4%	65.0	4.8	NR	NR	NR
Koh 2021	MCOT	1 month	105	10	9.5%	65.3	4 (2)	NR	NR	97 (12.6)
Kulach 2021	MCOT	1 month	72	1	1.4%	59.0	3.5 (1.6)	NR	NR	59 (4)
Kulach 2019	MCOT	7 days	78	7	9%	60.0	3.6	NR	NR	59 (4)
Lee 2015	Inpatient monitoring	3 days	127	12	9.4%	66.0	NR	NR	NR	NR
Liantinioti 2017	Inpatient monitoring	24h	184	13	7%	57.0	5 (IQR 4-5)	6 (range 3-10)	NR	NR
Liantinioti 2019	Inpatient monitoring	24h	373	29	8%	60.0	3.8 (1.3)	4 (range 3-10)	NR	NR
Lips 2020	ILR	30 months	88	19	21.6%	66.5	4 (range 2-7)	NR	NR	NR
Lumikari 2019	MCOT	1 month	57	7	12.3%	64.5	3.5 (1.2)	4.3 (5)	1 (IQR 0-1)	NR
Lumikari 2020	MCOT	2 weeks	15	1	6.7%	59. 5	NR	1.7 (2.4)	1 (IQR 0-1)	NR
Lyren 2020	MCOT	1 month	100	9	9%	67.6	4.4 (1.9)	NR	NR	NR
Makimoto 2017	ILR	12 months	146	30	21%	62.0	4.1 (1.3)	NR	NR	NR

Manina 2014	MCOT	4 days	114	12	24.3%	63.1	NR	6 (2.0)	NR	NR
Milstein 2020	ILR	12 months	343	67	5% (30 days) 21% (1 year)	68	3.5 (1.7)	NR	NR	57 (6)
Muller 2017	ILR	12 months	90	16	18%	57.7	3.4 (1.7)	NR	NR	59.1 (5.5)
Pagola 2018	MCOT	1 month	146	32	21.9%	76.0	5 (IQR 4-6)	5 (IQR 2-8)	NR	NR
Pagola 2021	MCOT	1 month	253	54	21.3%	74.4	NR	NR	NR	NR
Pedersen 2018	ILR	12 months	105	7	6.7%	65.4	NR	NR	NR	NR
Petrovicova 2021	ILR	12 months	100	24	24%	70.1	3	6.9	NR	NR
Poli 2016	ILR	12 months	75	25	33.3%	66.4	5	NR	NR	NR
Poulsen 2017	MCOT	1 month	95	20	21.1%	78	5	1	NR	NR
Rabinstein 2013 (61)	MCOT	3 weeks	64	3	4.7%	67.9	NR	NR	NR	NR
Reinke 2018	ILR	24 months	105	19	18%	64.4	4 (IQR 3-6)	2 (IQR 1-5)	NR	NR
Riordan 2020	ILR	24 months	293	74	25%	67.5	5.1 (1.3)	NR	NR	NR
Ritter 2013	ILR, MCOT	12 months (ILR) 7 days (MCOT)	60	10 (ILR) 1 (MCOT)	17%	63.0	4 (IQR 3-5)	NR	NR	NR
RubioCampal 2020	MCOT	3 weeks	50	11	22%	69.0	4 (1.5)	NR	NR	NR
Sanak 2015	MCOT	3 weeks	95	9	9.5%	39.1	2.7 (1.7)	9 (range 3-18)	NR	NR
Seow 2018	ILR	12 months	71	11	12.9% (6 months) 15.2%	61.9	NR	10 (11.3)	NR	55

					(12 months)					
Toyoda 2021	MCOT	1 week	206	13	6.3%	71.0	4.2 (1.3)	NR	NR	64.1 (IQR 61-70)
Triantafyllou 2020	ILR, Inpatient monitoring	18 months (ILR) 24h (Inpatient monitoring)	373 Holter; 123 ILR/ICM	26 (ILR) 28 (Inpatient monitoring)	7.5% (Holter) 21.1% (ICM)	60.0	3 (IQR 2-4)	3 (IQR 1-5)	NR	65.0 (6.7)
Tu 2014	MCOT	3 weeks	20	1	5.0% (28 days), 20.0% (2 years)	66.0	2 (IQR 1-3)	4 (IQR 1-7)	NR	NR
Ungar 2021	ILR	24 months	334	92	27.5%	67.4	NR	3 (3.0)	NR	NR
Victor 2018	ILR	24 months	65	12	29.2%	65.4	NR	4 (4.8)	NR	NR
Yayehd 2015	MCOT	3 weeks	39	1	2.6%	48.0	NR	3.5 (4.3)	NR	NR

Table S2. Covariate Details in Study Population

Appendix V: Meta-regression



Figure S1. Meta Regression for length of ECG monitoring



Figure S2. Meta Regression for mean patient age and mean CHA2DS2-VASc score



Figure S3. Meta Regression for mean patient NIHSS, Rankin, and LVEF

Appendix VI: Outlier identification

ECG monitoring modality	Study omitted	Subgroup	New pooled AF detection rate (95% CI)	I^2 (%)
ILR	Kitsiou 2021	Duration of monitoring 36 months	37.1% (0.7-98.0)	77.8
		Overall	18.4% (14.9-22.4)	86.1
	Cuadadro-Godia 2020	Duration of monitoring 30 months	30.6% (0.1-99.4)	84.4
		Overall	18.2% (14.9-22.0)	85.2
	Both	Overall	17.7% (14.5–21.3)	83.4
MCOT	Pagola 2021	Duration of monitoring <28 days	12.0% (8.2-17.1)	66.8
		AF cut-off 30s	10.0% (7.1-13.7)	62.4
		Timing of implantation <7 days	15.8% (9.1-26.0)	64.6
		Overall	10.6% (7.8-14.4)	67.4

Table S1. New pooled AF detection rates after removal of outliers



Figure S1. Leave-one-out analysis for ILRs for proportion



Figure S2. Leave-one-out analysis for ILRs for heterogeneity



Figure S3. Baujat plot for ILRs



Figure S4. Leave-one-out analysis for MCOTs for proportion



Figure S5. Leave-one-out analysis for MCOTs for heterogeneity



Figure S6. Baujat plot for MCOTs



Figure S7. Leave-one-out analysis for Inpatient monitoring for proportion



Figure S8. Leave-one-out analysis for Inpatient monitoring for heterogeneity



Figure S9. Baujat plot for Inpatient moniroting

Appendix VII: Quality assessment

Study ID	Item 1	Item 2	Item 3	Item 4	Item 5	Item 6	Item 7	Item 8	Item 9	Item 10	Total	Risk of bias
Acampa 2019	0	1	1	0	1	1	1	1	1	1	8	Low
Bettin 2019	0	1	1	0	1	1	1	1	1	1	8	Low
Christensen 2014	0	1	1	1	1	1	1	1	1	1	9	Low
Cotter 2013	0	1	1	1	1	1	1	1	1	1	9	Low
Cuadrado-Godia 2020	0	1	1	1	1	1	1	1	1	1	9	Low
DeAngelis 2020	0	1	1	1	1	1	1	1	1	1	9	Low
Fonseca 2014	0	0	1	1	1	1	1	1	1	1	8	Low
Israel 2017	0	1	1	1	1	1	1	1	1	1	9	Low
Jorfida 2016	0	1	1	0	1	1	1	1	1	1	8	Low
Jung 2020	0	1	1	1	1	1	1	1	1	1	9	Low
Kitsiou 2021	0	1	1	1	1	1	1	1	1	1	9	Low
Kulach 2019	0	1	1	0	1	0	1	0	1	1	6	Moderate

Kulach 2021	0	1	1	1	1	0	1	1	1	1	8	Low
Lee 2015	0	0	1	1	1	1	1	1	1	1	8	Low
Liantinioti 2017	0	1	1	1	1	1	1	1	1	1	9	Low
Liantinioti 2019	0	1	1	1	1	1	1	1	1	1	9	Low
Lips 2020	0	1	1	1	1	1	1	0	1	1	8	Low
Lumikari 2019	0	1	1	1	1	1	1	1	1	1	9	Low
Lumikari 2020	0	0	1	1	1	1	0	1	1	1	7	Moderate
Lyren 2020	1	1	1	1	1	1	0	1	1	1	9	Low
Makimoto 2017	0	1	1	0	1	1	1	1	1	1	8	Low
Manina 2014	0	1	1	1	1	1	1	1	1	1	9	Low
Milstein 2020	1	1	1	1	1	1	1	1	1	1	10	Low
Muller 2017	1	1	1	0	1	1	1	1	1	1	9	Low
Pagola 2018	1	1	1	1	1	1	0	0	1	1	8	Low
Pagola 2021	1	0	1	1	1	0	1	1	1	1	8	Low
Pedersen 2018	0	1	1	0	1	0	1	1	1	1	7	Moderate
Petrovicova 2021	0	1	1	0	1	1	1	1	1	1	8	Low

Poli 2016	0	1	1	1	1	1	1	0	1	1	8	Low
Poulsen 2017	0	1	1	1	1	1	0	1	1	1	8	Low
Rabinstein 2013	0	0	1	1	1	1	1	1	1	1	8	Low
Reinke 2018	0	1	1	0	1	1	1	1	1	1	8	Low
Riordan 2020	0	1	1	1	1	1	1	1	1	1	9	Low
Ritter 2013	0	1	1	0	1	1	1	1	1	1	8	Low
RubioCampal 2020	0	0	0	0	1	1	1	1	1	1	6	Moderate
Sanak 2015	0	0	1	1	1	1	1	1	1	1	8	Low
Seow 2018	0	1	0	0	1	1	1	1	1	1	7	Moderate
Triantafyllou 2020	0	1	1	0	1	1	1	0	1	1	7	Moderate
Tu 2014	0	0	1	1	1	1	1	1	1	1	8	Low
Victor 2018	0	1	1	1	1	1	1	0	1	1	8	Low
Yayehd 2015	0	0	1	1	1	0	0	1	1	1	6	Moderate
Flint 2012	1	1	1	0	1	0	1	1	1	1	8	Low

Toyoda 2021	1	1	1	1	1	1	1	1	1	1	10	Low
Ungar 2021	1	1	1	1	1	1	1	0	1	1	9	Low
Brachmann 2016	1	1	1	1	1	1	1	0	1	1	9	Low
Gladstone 2014	1	1	1	1	1	1	1	0	1	1	9	Low
Koh 2021	1	1	1	1	1	0	1	0	1	1	8	Low
≤4: High risk of bias 5-7: Moderate risk of bias 8-10: Low risk of bias												

Table S1: Risk of bias assessment

Appendix VIII: Publication bias



Figure S1. Funnel plot for the meta-analysis of atrial fibrillation proportion detected by implantable loop recorders



Figure S2. Funnel plot for the meta-analysis of atrial fibrillation proportion detected by Mobile Cardiac Outpatient Telemetry



Figure S3. Funnel plot for the meta-analysis of atrial fibrillation proportion detected by Mobile Cardiac Outpatient Telemetry with imputed studies by Trim & Fill method



Figure S4. Funnel plot for the meta-analysis of atrial fibrillation proportion detected by Inpatient Monitoring

Modality	Intercept (95% CI)	t	*p*
ILR	-0.784 (-3.90, 2.34)	-0.492	0.63
MCOT	-2.664 (-3.93, -1.39)	-4.113	**0.0007**
MCOT Trim & Fill	-0.404 (-1.87, 1.06)	-0.541	0.59
Inpatient Monitoring	-2.98 (-14.73, 8.77)	-0.497	0.64

Table S1: Egger's test results